BIRB 796 BS dose-dependently inhibits LPS-induced coagulation and fibrinolysis. Concentrations of F1 + 2 (A), tPA (B), PAI-1 (C), and PAPc (D) are shown. Subjects received an intravenous injection of LPS (4 ng/kg) at 0 hours, preceded by oral ingestion of placebo (□), 50 mg BIRB 796 BS (○), or 600 mg BIRB 796 BS (▴)at – 3 hours. Data are the mean ± SEM. Asterisks indicate a P value less than .05 versus placebo for the curve indicated, that is, high-dose BIRB 796 BS inhibited all parameters shown (all P < .05 vs placebo), and low-dose BIRB 796 BS inhibited tPA and PAPc (P < .05 vs placebo).